The Spartanburg Community Clinical Oncology Program (SCCOP), a consortium of three hospitals in Spartanburg County, SC with a population of about 236,000 persons with a cancer catchment area of 350,000 in upstate South Carolina and adjacent North Carolina will: 1) support the expansion of clinical research in our community; 2) stimulate quality care in our community through participation in protocol studies; 3) foster the growth and development of a scientifically viable community cancer network able to work closely with NCI-supported clinical cooperative groups and cancer centers; 4) support development of and community participation in interventional cancer control research including prevention, early detection, patient management, rehabilitation and continuing care; 5) involve primary care providers and other specialists in cancer control studies; and 6) increase the involvement of minority and underserved populations in clinical research. The combination of community physician expertise with NCI-approved treatment and cancer control clinical trials provides the opportunity for optimal transfer of the latest research findings to the community level. Award of this Cooperative Agreement will enable SCCOP to affiliate with the Southwest Oncology Group (National multi-specialty group), the Cancer Center of Wake Forest University (cancer center), the National Surgical Adjuvant Breast and Bowel Project (specialty base), and the University of Texas System M.D. Anderson Cancer Center (cancer center) as research bases. SCCOP will accrue a minimum of 50 credits per year to treatment clinical trials and a minimum of 50 credits per year to cancer control studies approved by the NCI and provided by the above research bases. Award of this Cooperative Agreement will provide support for a Program Coordinator, Data Coordinator, Cancer Control Coordinator, and a Secretary/Data Manager to provide the necessary data management, investigational drug management, quality control, and reporting requirements assistance to the six oncologist investigators in the successful achievement of the above goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035119-07
Application #
3557523
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-01
Project End
1991-05-31
Budget Start
1990-06-01
Budget End
1991-05-31
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Spartanburg Regional Medical Center
Department
Type
DUNS #
052072048
City
Spartanburg
State
SC
Country
United States
Zip Code
29303
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95

Showing the most recent 10 out of 202 publications